sulfadoxine/pyrimethamine

sulfadoxine/pyrimethamine
Drug name	Sulfadoxine/pyrimethamine
Routes of administration	Oral
Legal status	Prescription

sulfadoxine/pyrimethamine

Sulfadoxine/pyrimethamine is a fixed-dose combination antimalarial consisting of a sulfonamide and a dihydrofolate reductase inhibitor used historically for treatment and prevention of malaria in many regions including parts of Africa, Asia, and South America. Developed during the mid‑20th century, the combination has been deployed in public health programs by organizations such as the World Health Organization and the Bill & Melinda Gates Foundation for intermittent preventive therapy and outbreak control. Its use has declined in many settings because of widespread resistance associated with mutations tracked by research groups at institutions like the Centers for Disease Control and Prevention and the Wellcome Trust. Clinical deployment has intersected with policy decisions by entities including the European Medicines Agency and national ministries of health in countries such as Kenya, Uganda, and Nigeria.

Medical uses

Sulfadoxine/pyrimethamine has been used for treatment of uncomplicated Plasmodium falciparum malaria and for intermittent preventive therapy in pregnancy (IPTp) endorsed by the World Health Organization and implemented in programs by organizations like the United Nations Children's Fund and the Global Fund to Fight AIDS, Tuberculosis and Malaria. It has also been utilized in seasonal malaria chemoprevention campaigns coordinated with agencies such as the World Health Organization Regional Office for Africa and national programs in Mali, Senegal, and Burkina Faso. Clinical trials at centers including the London School of Hygiene & Tropical Medicine and the University of Oxford informed policy recommendations and comparative studies versus artemisinin-based combination therapies evaluated by the European Medicines Agency and the National Institutes of Health.

Mechanism of action

The combination acts synergistically by sequential blockade of folate synthesis in Plasmodium species, targeting enzymes analogous to bacterial targets described in classic work from researchers at Cambridge University and Harvard University. Sulfadoxine inhibits dihydropteroate synthase (DHPS) leading to impaired para-aminobenzoic acid utilization, while pyrimethamine inhibits dihydrofolate reductase (DHFR), preventing reduction of dihydrofolate to tetrahydrofolate required for nucleotide synthesis—mechanistic concepts elaborated in publications from institutes like the Pasteur Institute and the Max Planck Society. Resistance arises when point mutations in parasite DHFR and DHPS genes reduce drug binding affinity, a phenomenon documented in molecular epidemiology studies by teams from the London School of Hygiene & Tropical Medicine, the Wellcome Sanger Institute, and the Centers for Disease Control and Prevention.

Pharmacology

Pharmacokinetic and pharmacodynamic profiles were characterized in clinical pharmacology units at Johns Hopkins University and the University of Cape Town, showing long elimination half‑lives typical of sulfonamides and antifolates. Sulfadoxine exhibits prolonged plasma persistence enabling single‑dose regimens studied in trials sponsored by organizations like the World Health Organization and academic centers such as the Karolinska Institute. Pyrimethamine’s bioavailability and tissue distribution, including placental transfer examined in cohorts in Kenya and Tanzania, influenced its use in antenatal care protocols promoted by WHO technical programs. Drug–drug interaction assessments conducted by regulatory bodies like the European Medicines Agency considered coadministration with antiretrovirals used in programs by the President's Emergency Plan for AIDS Relief.

Adverse effects and contraindications

Adverse event profiles include hypersensitivity reactions ranging from mild rash to severe cutaneous adverse reactions such as Stevens–Johnson syndrome and toxic epidermal necrolysis reported in pharmacovigilance databases managed by the World Health Organization Collaborating Centre and the Uppsala Monitoring Centre. Hematologic effects such as megaloblastic anemia and agranulocytosis have been associated with antifolate exposure, prompting contraindications in patients with known folate deficiency or severe anemia as emphasized in guidance by the Royal College of Physicians and national formularies in South Africa and India. Use is contraindicated in individuals with known hypersensitivity to sulfonamides or pyrimethamine, and special caution is advised during first trimester pregnancy per advisories from the World Health Organization and obstetric societies including the International Federation of Gynecology and Obstetrics.

Resistance and efficacy

Efficacy has been compromised by spread of DHFR and DHPS mutations tracked by surveillance networks coordinated by the World Health Organization Global Malaria Programme, the Wellcome Trust, and academic consortia at institutions such as the Sanger Institute and Mahidol University. Regions with high prevalence of quintuple mutations—documented in studies from Cambodia, Mozambique, and Malawi—show markedly reduced clinical cure rates, prompting policy shifts toward artemisinin-based combination therapies supported by the World Health Organization and national malaria control programs in countries like Ghana and Zambia. Molecular marker monitoring and therapeutic efficacy studies led by the Centers for Disease Control and Prevention, London School of Hygiene & Tropical Medicine, and regional public health institutes inform ongoing decisions about IPTp deployment and chemoprevention strategies.

Dosage and administration

Historical single-dose treatment regimens were derived from clinical trials conducted at hospitals affiliated with University College London and the University of Nairobi, typically combining a single oral dose of sulfadoxine and pyrimethamine; IPTp schedules recommended by the World Health Organization advise doses administered at predefined antenatal visits coordinated with national ministries of health in countries such as Uganda and Tanzania. Administration guidance from regulatory agencies including the European Medicines Agency and pharmacopoeias emphasizes weight‑based dosing adjustments, contraindications in early pregnancy and severe anemia per clinical guidelines from the Royal College of Obstetricians and Gynaecologists and national obstetric societies. Where resistance limits effectiveness, national programs overseen by entities like the Global Fund to Fight AIDS, Tuberculosis and Malaria and bilateral partners have transitioned to alternative regimens validated by randomized controlled trials at institutions such as the London School of Hygiene & Tropical Medicine and the University of Oxford.

Category:Antimalarial agents